Mark Foley, Revance CEO (Revance via Vimeo)
FDA rejects Revance's pitch for Botox competitor as biotech blames manufacturing issues
The FDA has told Revance Therapeutics that, no, it won’t be able to turn those frowns upside down.
Regulators issued a CRL to the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
